August 2009
Current Medical Literature: Dermatology;2009, Vol. 14 Issue 3, p62
Academic Journal
The article presents updates on the treatment of skin diseases. An updated guideline for the use of methotrexate in the treatment of psoriasis was released by the Medical Board of National Psoriasis Foundation. Systemic corticosteroids were considered as mainstays for the treatment of chronic skin diseases, especially on osteopenia and osteoporosis. A study is presented on the efficacy of corticosteroids and antimalarials in treating Discoid lupus erythematosus.


Related Articles

  • Treatment Options For Psoriasis Expanding. Guttman, Cheryl // Dermatology Times;May99, Vol. 20 Issue 5, p3 

    Identifies emerging therapies for the treatment of psoriasis in the United States. Narrow-band ultraviolet; Mycophenolate mofetil; 6-thioguanine; Corticosteroid foams for scalp use; Biotechnology agents for blocking T-cell activation.

  • Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Sakthiswary, R; Suresh, E // Lupus;Mar2014, Vol. 23 Issue 3, p225 

    The article presents a study which evaluates the efficacy of methotrexate (MTX) in the treatment of adult patients with systemic lupus erythematosus (SLE). To screen for studies that examined MTX efficacy, a comprehensive search was performed in MEDLINE, EMBASE and the Cochrane Controlled Trials...

  • Current Treatment Strategies: Collagen Vascular Diseases in Children. Palit, Aparna; Inamadar, Arun C. // Indian Journal of Dermatology;Nov/Dec2012, Vol. 57 Issue 6, p449 

    Of the various collagen vascular diseases seen in pediatric age group, discoid lupus erythematosus, systemic lupus erythematosus, neonatal lupus erythematosus, juvenile dermatomyositis and childhood scleroderma are common and of practical importance to clinicians. Various treatment modalities of...

  • BJD Editor's Choice.  // Journal of Investigative Dermatology;Oct2012, Vol. 132 Issue 10, p2310 

    The article offers information related to the treatment of several skin disorders. It informs that etanercept plus methotrexate can be a viable regimen in the patients suffering from psoriasis. It further states that using oral tofacitinib for treating psoriasis results a significant clinical...

  • Hydroxychloroquine: past, present, future. Petri, M. // Lupus;1998, Vol. 7 Issue 2, p65 

    Editorial. Discusses hydroxychloroquine as one of the most commonly prescribed medications for systematic lupus erythematosus (SLE). Mechanism of action of antimalarials; Results of clinical trials of antimalaruials in SLE.

  • Combination of calcipotriol and betamethasone in psoriasis treatment. KRUGLOVA, L. S.; MORDOVTSEVA, V. V.; ZHUKOVA, O. V.; SEROV, D. N. // Klinicheskaya Dermatologia I Venerologia;2014, Issue 6, p54 

    Fixed-dose combination of vitamin D3 analog and glucocorticosteroid betamethasone (calcipotriol 50 mg/kg and betamethasone 0.5 mg/kg) is recommended for daily use in patients with different clinical forms of psoriasis. The main mechanisms of action include proliferation suppression and...

  • Risk-Benefit Assessment of Methotrexate in the Treatment of Severe Psoriasis. Kuijpers, A.L.; van der Kerkhof, P.C.M. // American Journal of Clinical Dermatology;Jan/Feb2000, Vol. 1 Issue 1, p27 

    Methotrexate is an established and highly effective systemic treatment for severe psoriasis, including the pustular and erythrodermic forms. It has been widely used during the last 3 decades. For this reason, the long term adverse effects of methotrexate are well known, in contrast to other...

  • Mid-potency topical corticosteroid for dermatoses.  // Modern Medicine;Mar94, Vol. 62 Issue 3, p25 

    Reports that the mid-potency topical corticosteroid prednicarbate emollient cream has been approved for relieving the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Application of the cream; Side-effects.

  • Company cites cosmetic differences in corticosteroids. Nemec, John // Dermatology Times;Jan1999, Vol. 20 Issue 1, p49 

    Focuses on the need for dermatologists to look into cosmetic considerations when selecting topical corticosteroids for inflammatory skin disease patients according to Rukmini Rajagopalan, associated director of biostatics and health economics at Glaxo Wellcome Inc. Results of physician...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics